Kent Stock, DO
Infectious Disease · Charleston, SCNPI 1356331904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.
Across 383 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$1K
- Gilead$964
- AbbVie$764
- Viiv Healthcare Company$763
- Merck$740
- Astellas Pharma US Inc$638
- plus $2K from 19 others
Across 274 payments — averaging $3186.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$535K
- Biohaven Pharmaceuticals, Inc.$154K
- Octapharma USA, Inc.$108K
- Biohaven Pharmaceutical Holding Company Ltd.$71K
- Roche Products Limited$5K
- Amgen$161
What the payments were for
- Consulting fees$380%
- Food & beverage$7,29295%
- Education$3164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 62 | $1,459 |
| Gilead | 43 | $964 |
| AbbVie(2 entities) | 48 | $764 |
| Viiv Healthcare Company | 43 | $763 |
| Merck | 53 | $740 |
| Astellas Pharma US Inc | 23 | $638 |
| Melinta Therapeutics, LLC | 21 | $427 |
| Shionogi Inc | 13 | $359 |
| Theratechnologies Inc. | 13 | $286 |
| Paratek Pharmaceuticals, Inc. | 15 | $279 |
| Johnson & Johnson(2 entities) | 13 | $217 |
| La Jolla Pharmaceutical Company | 6 | $122 |
| Cipla USA Inc. | 1 | $105 |
| Ferring Pharmaceuticals Inc. | 3 | $72 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $63 |
| ADMA Biomanufacturing LLC | 2 | $61 |
| Mayne Pharma Commercial LLC | 3 | $60 |
| Pfizer | 3 | $60 |
| Napo Pharmaceuticals Inc | 4 | $50 |
| Nabriva Therapeutics, PLC | 3 | $47 |
| Grifols USA, LLC | 2 | $37 |
| Cumberland Pharmaceuticals, Inc. | 2 | $31 |
| Dynavax Technologies Corporation | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Vyera Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,645 in reported general payments places this provider in the 85th percentile of 102 infectious disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 32 | $477,074 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 102 | $427,751 |
| NuzyraOmadacycline Tosylate | 16 | $246,706 |
| IsentressRaltegravir Potassium | 30 | $59,122 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $50,490 |
| EdurantRilpivirine Hcl | 33 | $47,991 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $41,002 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $36,044 |
| TivicayDolutegravir Sodium | 15 | $33,315 |
| PrezcobixDarunavir/Cobicistat | 12 | $28,918 |
| Darunavir | 13 | $21,984 |
| PifeltroDoravirine | 11 | $18,294 |
| Vancomycin Hcl | 48 | $7,520 |
| Cefepime Hcl | 25 | $5,752 |
| Azithromycin | 91 | $2,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $964 | $514,285132 claims |
| Insmed, Inc.Arikayce | $1,459 | $477,07432 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $279 | $246,70616 claims |
| MerckIsentress, Pifeltro | $740 | $77,41541 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $763 | $74,31729 claims |
| Johnson & JohnsonPrezcobix | $217 | $28,91812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 infectious disease providers in South Carolina.
Other infectious disease in Charleston
- Toby FugateCharleston$136K
- John McKinnonCharleston$85K
- John GnannCharleston$39K
- Scott CurryCharleston$8K
- Cameron SelentCharleston$6K
- Taylor StrowmanCharleston$5K
- Eric MeissnerCharleston$4K
- Drew CharlesCharleston$2K
- Susan DormanCharleston$2K
- Joseph JohnCharleston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.